A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Trial Profile

A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Liver disorders; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Biotie Therapies Corp.
  • Most Recent Events

    • 20 Nov 2017 Status changed from recruiting to discontinued, according to an Acorda Therapeutics media release. The company is discontinuing dosing of all participants based on previously disclosed agranulocytosis and associated serious adverse events. the Company concluded that it could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.
    • 14 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top